mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland.

Dear Editor,

Large-scale vaccination programs were incepted in response to the coronavirus disease 2019 (COVID-19) pandemic. Although high effectiveness was initially indicated [1], public-health factors and emerging virus variants have contributed to changes in characteristics of critically ill COVID-19 patients [2]. To monitor the effects of the vaccination program on the development of critical illness due to COVID-19, we compared the characteristics and outcome of vaccinated versus non-vaccinated patients admitted to the intensive care unit (ICU) via the prospective observational Risk Stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry [3]. Mixed-model analysis accounted for potential treatment center effects, and analysis was adjusted for age, sex and immunosuppression. To minimize variation in viral epidemiology, vaccination programs and ICU resources, we focused only on patients admitted to ICUs in Switzerland (Appendix S1).

Of 4351 critically ill COVID-19 patients enrolled internationally by September 30th, 2021, 2253 were treated in Switzerland. Within this cohort, 964 patients admitted to the ICU during the vaccination program were included (Fig. S1). 10.5 million vaccine doses were inoculated in 5.6 million individuals during this period (64.3 population-%, Fig. S2 A/B). 33 patients were admitted to the ICU median interquartile range, (IQR) 92.5 (22.3–110.3) days after the second vaccination (3.4% of ICU admissions, 30% BNT162b2 [Pfizer/BioNTech], 70% mRNA-1273 [Moderna]), versus 931 non-vaccinated patients [ICU/population vaccinated-non-vaccinated ratio was 0.035/1.29, OR (CI) 0.027 (0.019–0.039), p < 0.001].

Comparative statistics between vaccinated and non-vaccinated patients are detailed in Fig. 1 and Table S1. Vaccinated patients were 6.8 (CI 2.0–11.6) years older (p < 0.01) and had more comorbidities [RR (CI) 1.5 (1.1–2.1), p = 0.03], especially immunosuppression [OR (CI) 5.8 (2.7–13), p < 0.0001]. They presented at ICU admission with lower respiratory Sequential Organ Failure Assessment (SOFA) sub-score, need for mechanical ventilation, and 3 point lower overall SOFA score, alongside lower cardiovascular, coagulatory, renal and central nervous system sub-scores. ICU length-of-stay was reduced by 6 (CI − 11.7 to − 0.5) days in survivors (p = 0.03), with similar ICU mortality at 23.3 versus 22.4% [HR (CI) 1.4 (0.6–3), p = 0.41]. Effects were preserved or strengthened by adjustment.

Fig. 1

Effect of vaccination status on the patient characteristics and initial treatment at ICU admission (A), and on the outcome of critically ill COVID-19 patients (B), showing for vaccinated patients admitted to the ICU, less severe lung and systemic organ failure, need for mechanical ventilation and shorter ICU length of stay, yet still similar ICU mortality despite older age and elevated risk profile. The age distribution of patients admitted to the ICU shows a marked right-shift, with only 12% of the vaccinated critically ill patients below the age of 60 years (C). Blue dots and lines represent the estimate and 95% CI of mixed model analysis with vaccination status entered as fixed effect and treatment center as random effect, whereas red dots and lines represent the estimate and 95% CI of adjusted mixed model analysis with age, sex and presence of immunosuppression-related disease as pre-existing condition as additional fixed effects. All included patients are represented in panel (A, n = 964), whereas panel (B) encompasses patients discharged from the ICU by September 30th, 2021 for the crude analysis graph (n = 915), and ICU survivors for the adjusted analysis graph (n = 710). ICU mortality estimates were modeled using a Cox proportional hazards model, with an underlying time scale of ICU admission until date of death or date of discharge which was defined as censoring event, with ICU mortality entered as event and ICU survival entered as censored event. Estimates are given as the mean difference (CI) for continuous variables, RR (CI) for counts, OR (CI) for binary categorical variables, and HR (CI) for survival analysis, the secondary scale applies to the reporting of RR, OR and HR as denoted (*). The vertical grey line represents the line of no effect. Estimates to the right of the grey line are associated with the vaccination, and to the left, with the lack of vaccination scilicet inversely with the vaccination. Complete results for crude and adjusted analyses in the overall and subpopulations are listed in Supplementary Table S1 and Supplementary Table S2. RR, rate ratio; OR, odds ratio; HR, hazard ratio; CI, 95% confidence interval

Near real-time registry data thus confirm previous implications of reduced COVID-19 hospitalization rates with increasing vaccination-ratio [4], and suggest an even larger effect regarding the development of critical illness by showing that less than 4% of COVID-19 patients admitted to ICU in the first 9 months of the vaccination program in Switzerland were vaccinated. Two main findings indicate a positive effect of the vaccination program. First, despite older age and elevated risk profile, vaccinated ICU patients had less severe lung and systemic organ failure, need for mechanical ventilation and shorter ICU length-of-stay, yet still similar ICU mortality. A trend towards higher D-dimer and lower ferritin levels could indicate differences in coagulatory activation and immune dysregulation, warranting further investigation. Second, a reduced disease severity was observed as compared to non-vaccinated patients despite an increasing prevalence of virus variants (Fig. S2 C) and reports of breakthrough infections in vaccinated individuals [5]. Nevertheless, the higher prevalence of comorbidities in vaccinated patients, together with previously described, attenuated in vitro vaccine response in immunocompromised patients, emphasize the importance of ongoing improvements to vaccination regimes, e.g., by adding booster doses.

In conclusion, our data strongly support a protective effect of the mRNA-based COVID-19 vaccines in preventing critical illness and unfavorable disease course even in patients with known risk factors for COVID-19 and indicate an important role in relieving ICU resources.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 478 kb)